An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Public ClinicalTrials.gov record NCT02041533. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to show that Nivolumab will improve progression free survival in subjects with strongly Stage IV or Recurrent PD-L1+ non-small cell lung cancer when compared to chemotherapy
Study identification
- NCT ID
- NCT02041533
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 541 participants
Conditions and interventions
Interventions
- Nivolumab Biological
- Gemcitabine Drug
- Cisplatin Drug
- Carboplatin Drug
- Paclitaxel Drug
- Pemetrexed Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 27, 2014 (Actual)
- Primary completion
- Jul 1, 2016 (Actual)
- Completion
- May 27, 2022 (Actual)
- Last update posted
- Mar 2, 2023
2014 – 2022
United States locations
- U.S. sites
- 36
- U.S. states
- 21
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southern Cancer Center, Inc. | Mobile | Alabama | 36608 | — |
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| Local Institution - 0034 | Tucson | Arizona | 85704 | — |
| Local Institution - 0016 | Stanford | California | 94305-5826 | — |
| University Of Colorado Hosp | Aurora | Colorado | 80045 | — |
| Local Institution - 0020 | New Haven | Connecticut | 06520 | — |
| Local Institution - 0030 | Miami | Florida | 33176 | — |
| Local Institution - 0033 | Ocala | Florida | 34471 | — |
| H. Lee Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Local Institution - 0010 | Atlanta | Georgia | 30322 | — |
| Northwest Georgia Oncology Center, P.C. | Marietta | Georgia | 30060 | — |
| Local Institution - 0037 | Chicago | Illinois | 60612-3841 | — |
| Local Institution - 0014 | Lexington | Kentucky | 40503 | — |
| Crescent City Research Consortium, LLC | Marrero | Louisiana | 70072 | — |
| Local Institution - 0024 | Baltimore | Maryland | 21287 | — |
| Local Institution - 0036 | Boston | Massachusetts | 02114 | — |
| Local Institution - 0070 | Boston | Massachusetts | 02215 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Local Institution - 0009 | New York | New York | 10016 | — |
| Local Institution - 0005 | New York | New York | 10065 | — |
| University Of North Carolina At Chapel Hill | Chapel Hill | North Carolina | 27599-7305 | — |
| Local Institution - 0003 | Durham | North Carolina | 27710 | — |
| Local Institution - 0012 | Cleveland | Ohio | 44106 | — |
| Local Institution - 0027 | Columbus | Ohio | 43210 | — |
| Oregon Health & Science University | Portland | Oregon | 97239-3098 | — |
| Local Institution - 0007 | Allentown | Pennsylvania | 18103 | — |
| Local Institution - 0054 | Philadelphia | Pennsylvania | 19104 | — |
| Local Institution - 0002 | Philadelphia | Pennsylvania | 19111 | — |
| Local Institution - 0018 | Pittsburgh | Pennsylvania | 15232 | — |
| Local Institution - 0011 | Charleston | South Carolina | 29425 | — |
| Local Institution - 0038 | Greenville | South Carolina | 29601 | — |
| Local Institution - 0008 | Nashville | Tennessee | 37232-6307 | — |
| Local Institution - 0006 | Dallas | Texas | 75390 | — |
| Local Institution - 0023 | Houston | Texas | 77030 | — |
| Cancer Centers of South Texas | San Antonio | Texas | 78212 | — |
| Local Institution - 0029 | Yakima | Washington | 98902 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 105 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02041533, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 2, 2023 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02041533 live on ClinicalTrials.gov.